Full-Life Technologies announce that it has closed on an important land purchase in Wallonia, Belgium, and signed a purchase agreement to build a state-of-the-art, manufacturing facility to produce radiopharmaceuticals to Good Manufacturing Practice (GMP)

Full-Life Technologies today announced the appointments of Steffen Heeger, MD, PhD, as Chief Medical Officer (CMO) and Fa Liu, PhD as Chief Scientific Officer (CSO).

Acquisition accelerates Full-Life's transformation into clinical stage radiopharmaceutical company, leveraging its European-focused Radiotechnology and Development Platform

Shanghai, China & Brussels, Belgium - August 10, 2022 - Full-Life Technologies Co., Ltd. (“Full-Life”) today announced two key appointments to its Radioisotope Technology leadership team and the establishment of a Radioisotope Technology Advisory Boar

Full-Life Technologies (“Full-Life”) today announced it completed a $37 million (USD) Series A financing round to advance the development of its radiopharmaceutical oncology product pipeline and its radiotechnology production platform.